Navigation Links
Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study in IgA Nephropathy with Blisibimod
Date:6/24/2013

p>

About B-Cell Activating Factor (BAFF) and Blisibimod

BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. Multiple clinical studies with other BAFF antagonists recently have reported on the potential positive role on BAFF inhibitors in treating lupus and rheumatoid arthritis with concomitant decreases in B-cells, plasma cells and autoantibodies. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel protein compromised of high-affinity BAFF binding domains fused to a human Fc domain, called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune disorders.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about the Company's expectations with respect to its proposed offering, including its intention to offer and sell shares, its intention to grant the underwriters an option to purchase additional shares and its intended use of proceeds from the offering.  Such statements are based on the Company's e
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
10. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today reported financial ... "During the quarter, we achieved a key ... securing a partner to accelerate the development and commercialization of ... we do not have a commercial presence while also retaining ... the value of PIXUVRI for CTI and help us achieve ...
(Date:10/30/2014)... -- Today Eli Lilly and Company (NYSE: ... program to increase the global supply of medicines for ... Lilly donating manufacturing technology and know-how for two antibiotics ... India , Russia ... all MDR-TB ,hot spots., It also served as the ...
(Date:10/27/2014)... NEW YORK , Oct. 27, 2014  In the last ... parts of Africa to a worldwide crisis ... down with the virus and died, and two nurses were infected. ... how this could happen, the use of modern technology, such as ... went largely unnoticed. This week, InformationWeek Healthcare Editor ...
Breaking Medicine Technology:CTI BioPharma Reports Third Quarter 2014 Financial Results 2CTI BioPharma Reports Third Quarter 2014 Financial Results 3CTI BioPharma Reports Third Quarter 2014 Financial Results 4CTI BioPharma Reports Third Quarter 2014 Financial Results 5CTI BioPharma Reports Third Quarter 2014 Financial Results 6CTI BioPharma Reports Third Quarter 2014 Financial Results 7CTI BioPharma Reports Third Quarter 2014 Financial Results 8CTI BioPharma Reports Third Quarter 2014 Financial Results 9CTI BioPharma Reports Third Quarter 2014 Financial Results 10CTI BioPharma Reports Third Quarter 2014 Financial Results 11CTI BioPharma Reports Third Quarter 2014 Financial Results 12Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4EHRs in the Age of Ebola: Discuss on InformationWeek 2EHRs in the Age of Ebola: Discuss on InformationWeek 3
... ROCKVILLE, Md., July 6 A procedure that sends targeted ... to treat a common type of irregular heartbeat, but little ... methods and circumstances for applying it, according to a new ... , , The report examines the use of a ...
... The Netherlands, July 6 Three new small and,medium ... - have joined public-private partnership TI Pharma by,participating in ... diseases, have a total budget of nearly 6 million ... formed by Syncom, Synvolux Therapeutics, and,University Medical Center Groningen, ...
Cached Medicine Technology:New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation 2New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation 3New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects 2
(Date:10/30/2014)... Nutrition Leaders, a popular online retailer of ... more, is currently hosting a sweepstakes on its official ... open to U.S. residents age 18 and over, and ... lucky winner will then be selected at random from ... to NutritionLeaders.com. , Nutrition Leaders’ managing director Kimba Vasquez ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Graphics, coding, ... are synonymous with the craft of web design and ... website. Yet a simpler solution to create a website ... pictures, videos, contact information, customer reviews and Facebook posts ... "It is the next evolution of how a ...
(Date:10/30/2014)... 2014 High efficacy and low ... the medical-grade skin care domain: Cosmederm, the specialty ... potent topical dermatological products, today announces the launch ... with patented COSMEDERM®-7 anti-irritant technology. , Formulated ... and 70%) and a low pH (pH 1.2 ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 PreDiabetes ... PreD Store shoppers with a supply of ... meals to reduce post-meal blood sugar spikes. Learning how ... is an important part of a diabetes prevention plan. ... will receive one complimentary tube of sugardown. The offer ...
(Date:10/30/2014)... Haven, CT (PRWEB) October 30, 2014 ... categories are raising questions about the impact of traditional ... the marketing method most likely to influence a purchasing ... research poll of 525 consumers conducted by radio marketing ... four product categories, isolating the results of respondents who ...
Breaking Medicine News(10 mins):Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3
... Most breast cancer surgeons, practices do not follow ... to a new study from researchers at the University ... with other specialists and providing resources and education to ... mantra for multidisciplinary decision-making and care intake for patients, ...
... options for low-risk prostate cancer found that the rates ... most common treatment approaches, although costs can vary considerably. ... Clinical and Economic Review (ICER), a leader in comparative ... for Technology Assessment. Bringing together the ...
... CHILDREN MAY HAVE POORER LUNG FUNCTION ,A new ... midlife may be influenced by several factors, including birth weight, ... Kingdom analyzed health data from 252 patients, all aged 14 ... patients at age 49 to 51. Results showed that several ...
... Energy and Commerce as part of an investigation into preventable ... report recommending further restrictions regarding duty hours for resident physicians ... safety, according to an article published in the January issue ... (JACR). In 2003, the Accreditation Council for ...
... York, NY, January 4, 2010 Knee osteoarthritis (OA) accounts ... Running, although it has proven cardiovascular and other health benefits, ... a study published in the December 2009 issue of ... compared the effects on knee, hip and ankle joint motions ...
... Extremity War Injuries Symposium was held in Washington, D.C., ... surgeons, researchers, experts from governmental agencies, and others to ... Iraq and Afghanistan and to discuss ways to synergize ... summarizing the findings from the symposium is published in ...
Cached Medicine News:Health News:Few breast cancer surgeons follow quality of care standards, U-M study finds 2Health News:Report suggests similar effectiveness among options for managing low-risk prostate cancer 2Health News:Report suggests similar effectiveness among options for managing low-risk prostate cancer 3Health News:News briefs from the January issue of Chest 2Health News:Institute of Medicine recommends stricter resident duty hour regulations to prevent medical errors 2Health News:Running shoes may cause damage to knees, hips and ankles 2Health News:Extremity war injuries: More research is needed 2Health News:Extremity war injuries: More research is needed 3
... iVAD*, implantable ventricular assist ... implantable device used by ... and outflow conduits are ... and anatomically positioned to ...
Datascope presents a unique new product for post-hemostasis puncture site management. Safeguard is the first product ever to combine a built-in inflatable bulb and a sterile dressing- providing adjus...
The Icy catheter is inserted into the femoral vein and resides in the inferior vena cava. Saline flow within the balloons creates a proprietary vortex flow pattern which maximizes heat exchange with...
...
Medicine Products: